North America Dry Eye Disease Market Forecast 2023-2032

The North America dry eye disease market growth is anticipated to progress at a CAGR of 5.20% during the forecast period, 2023-2032. The rising prevalence of dry eye, the increasing demand for dry eye products, the surging healthcare expenditure, and the growing government support are among the key factors set to propel the regional market's growth.

MARKET INSIGHTS

Canada and the United States are assessed for the North America dry eye disease market growth analysis. As per the article published in 2019 by Barbara Caffery, approximately 6 million Canadian adults are likely to have been diagnosed by dry eye disease. The condition substantially impacts the vision-related quality of life, thereby affecting activities like reading, driving, using mobile phones and computers, as well as watching television.

On the other hand, gels, artificial tear drops, and ointments available over the counter help treat dry eye disease. The approval of Xiidra in Canada has provided patients with a novel option to address both the symptoms and indications of dry eye disease. In 2018, Shire Pharma Canada ULC (Shire Canada) and Shire PLC announced that the twice-daily eye drops solution, Xiidra (lifitegrast ophthalmic solution 5%), has been prescribed for the treatment of the indications and symptoms of dry eye disease in adults. As a result, these factors are expected to fuel the dry eye disease market growth in North America over the forecasting years.

COMPETITIVE INSIGHTS

Some of the leading firms operating in the market are Bausch Health Companies Inc, Santen Pharmaceutical Co Ltd, Abbvie Inc (Allergan PLC), Johnson & Johnson, etc.

Our report offerings include:

Explore key findings of the overall market
Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
Market Segmentation caters to a thorough assessment of key segments with their market estimations
Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

Product Code: 39621

1. RESEARCH SCOPE & METHODOLOGY

1.1. STUDY OBJECTIVES
1.2. METHODOLOGY
1.3. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
2.3. SCOPE OF STUDY
2.4. CRISIS SCENARIO ANALYSIS
2.5. MAJOR MARKET FINDINGS
- 2.5.1. AIR POLLUTION IS A MAJOR CAUSE OF EYE DISEASES
- 2.5.2. COVID-19 CONTRIBUTED TO A HIGH NUMBER OF DRY EYE DISEASE CASES
- 2.5.3. ASIAN RACE IS AT HIGHER RISK OF DEVELOPING DRY EYE DISEASE
- 2.5.4. EXCESSIVE SCREEN TIME CAN INDUCE DRY EYE SYMPTOMS

3. MARKET DYNAMICS

3.1. KEY DRIVERS
- 3.1.1. INTRODUCTION OF NOVEL DIAGNOSTIC TECHNIQUES FOR DRY EYE DISEASE
- 3.1.2. LAUNCH OF PROMISING PIPELINE PRODUCTS FOR DRY EYE DISEASE
- 3.1.3. GROWING INCIDENCE AND PREVALENCE OF DRY EYE AMONG DIFFERENT AGE GROUPS
3.2. KEY RESTRAINTS
- 3.2.1. RISK OF SIDE EFFECTS
- 3.2.2. SUBSTITUTE THERAPIES
- 3.2.3. EXPENSIVE SPECIALTY PRODUCTS AND COMPLEX REIMBURSEMENT SCENARIO

4. KEY ANALYTICS

4.1. PARENT MARKET ANALYSIS
4.2. KEY MARKET TRENDS
4.3. PORTER'S FIVE FORCES ANALYSIS
- 4.3.1. BUYERS POWER
- 4.3.2. SUPPLIERS POWER
- 4.3.3. SUBSTITUTION
- 4.3.4. NEW ENTRANTS
- 4.3.5. INDUSTRY RIVALRY
4.4. GROWTH PROSPECT MAPPING
4.5. MARKET MATURITY ANALYSIS
4.6. MARKET CONCENTRATION ANALYSIS
4.7. VALUE CHAIN ANALYSIS
- 4.7.1. RESEARCH AND DEVELOPMENT
- 4.7.2. MANUFACTURING
- 4.7.3. DISTRIBUTORS
- 4.7.4. POST-SALES MONITORING

5. MARKET BY TYPE

5.1. OTC
5.2. PRESCRIPTION

6. MARKET BY PRODUCT

6.1. ANTI-INFLAMMATORY DRUGS
- 6.1.1. CYCLOSPORINE
- 6.1.2. CORTICOSTEROID
- 6.1.3. OTHER ANTI-INFLAMMATORY DRUGS
6.2. ARTIFICIAL TEARS
6.3. PUNCTAL PLUGS
6.4. SECRETAGOGUES
6.5. OTHER PRODUCTS

7. MARKET BY DISTRIBUTION CHANNEL

7.1. HOSPITAL PHARMACIES
7.2. INDEPENDENT PHARMACIES AND DRUGSTORES
7.3. ONLINE PHARMACIES

8. GEOGRAPHICAL ANALYSIS

8.1. NORTH AMERICA
- 8.1.1. MARKET SIZE & ESTIMATES
- 8.1.2. NORTH AMERICA DRY EYE DISEASE MARKET DRIVERS
- 8.1.3. NORTH AMERICA DRY EYE DISEASE MARKET CHALLENGES
- 8.1.4. NORTH AMERICA DRY EYE DISEASE MARKET REGULATORY FRAMEWORK
- 8.1.5. KEY PLAYERS IN NORTH AMERICA DRY EYE DISEASE MARKET
- 8.1.6. COUNTRY ANALYSIS
  - 8.1.6.1. UNITED STATES
  - 8.1.6.1.1. UNITED STATES DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
  - 8.1.6.2. CANADA
  - 8.1.6.2.1. CANADA DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES

9. COMPETITIVE LANDSCAPE

9.1. KEY STRATEGIC DEVELOPMENTS
- 9.1.1. MERGERS & ACQUISITIONS
- 9.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
- 9.1.3. PARTNERSHIPS & AGREEMENTS
- 9.1.4. BUSINESS EXPANSIONS & DIVESTITURES
9.2. COMPANY PROFILES
- 9.2.1. AFT PHARMACEUTICALS
- 9.2.2. ALCON
- 9.2.3. ALLERGAN PLC (ACQUIRED BY ABBVIE)
- 9.2.4. BAUSCH HEALTH COMPANIES INC
- 9.2.5. JOHNSON & JOHNSON
- 9.2.6. LUMENIS
- 9.2.7. NOVALIQ GMBH
- 9.2.8. NOVARTIS AG
- 9.2.9. OASIS MEDICAL
- 9.2.10. OTSUKA PHARMACEUTICAL CO LTD
- 9.2.11. SANTEN PHARMACEUTICAL CO LTD
- 9.2.12. SENTISS PHARMA PRIVATE LIMITED
- 9.2.13. SUN PHARMACEUTICAL INDUSTRIES LTD
- 9.2.14. TEVA PHARMACEUTICAL INDUSTRIES LTD
- 9.2.15. VISUFARMA

Product Code: 39621

LIST OF TABLES

TABLE 1: MARKET SNAPSHOT - DRY EYE DISEASE
TABLE 2: NORTH AMERICA DRY EYE DISEASE MARKET, BY TYPE, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 3: NORTH AMERICA DRY EYE DISEASE MARKET, BY TYPE, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 4: NORTH AMERICA DRY EYE DISEASE MARKET, BY PRODUCT, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 5: NORTH AMERICA DRY EYE DISEASE MARKET, BY PRODUCT, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 6: NORTH AMERICA DRY EYE DISEASE MARKET, BY ANTI-INFLAMMATORY DRUGS, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 7: NORTH AMERICA DRY EYE DISEASE MARKET, BY ANTI-INFLAMMATORY DRUGS, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 8: NORTH AMERICA DRY EYE DISEASE MARKET, BY DISTRIBUTION CHANNEL, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 9: NORTH AMERICA DRY EYE DISEASE MARKET, BY DISTRIBUTION CHANNEL, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 10: NORTH AMERICA DRY EYE DISEASE MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 11: NORTH AMERICA DRY EYE DISEASE MARKET, BY COUNTRY, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 12: NORTH AMERICA DRY EYE DISEASE MARKET REGULATORY FRAMEWORK
TABLE 13: KEY PLAYERS OPERATING IN NORTH AMERICA DRY EYE DISEASE MARKET
TABLE 14: LIST OF MERGERS & ACQUISITIONS
TABLE 15: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
TABLE 16: LIST OF PARTNERSHIPS & AGREEMENTS
TABLE 17: LIST OF BUSINESS EXPANSIONS & DIVESTITURES

LIST OF FIGURES

FIGURE 1: KEY MARKET TRENDS
FIGURE 2: PORTER'S FIVE FORCES ANALYSIS
FIGURE 3: GROWTH PROSPECT MAPPING FOR NORTH AMERICA
FIGURE 4: MARKET MATURITY ANALYSIS
FIGURE 5: MARKET CONCENTRATION ANALYSIS
FIGURE 6: VALUE CHAIN ANALYSIS
FIGURE 7: NORTH AMERICA DRY EYE DISEASE MARKET, GROWTH POTENTIAL, BY TYPE, IN 2022
FIGURE 8: NORTH AMERICA DRY EYE DISEASE MARKET, BY OTC, 2023-2032 (IN $ MILLION)
FIGURE 9: NORTH AMERICA DRY EYE DISEASE MARKET, BY PRESCRIPTION, 2023-2032 (IN $ MILLION)
FIGURE 10: NORTH AMERICA DRY EYE DISEASE MARKET, GROWTH POTENTIAL, BY PRODUCT, IN 2022
FIGURE 11: NORTH AMERICA DRY EYE DISEASE MARKET, BY ANTI-INFLAMMATORY DRUGS, 2023-2032 (IN $ MILLION)
FIGURE 12: NORTH AMERICA DRY EYE DISEASE MARKET, GROWTH POTENTIAL, BY ANTI-INFLAMMATORY DRUGS, IN 2022
FIGURE 13: NORTH AMERICA DRY EYE DISEASE MARKET, BY CYCLOSPORINE, 2023-2032 (IN $ MILLION)
FIGURE 14: NORTH AMERICA DRY EYE DISEASE MARKET, BY CORTICOSTEROID, 2023-2032 (IN $ MILLION)
FIGURE 15: NORTH AMERICA DRY EYE DISEASE MARKET, BY OTHER ANTI-INFLAMMATORY DRUGS, 2023-2032 (IN $ MILLION)
FIGURE 16: NORTH AMERICA DRY EYE DISEASE MARKET, BY ARTIFICIAL TEARS, 2023-2032 (IN $ MILLION)
FIGURE 17: NORTH AMERICA DRY EYE DISEASE MARKET, BY PUNCTAL PLUGS, 2023-2032 (IN $ MILLION)
FIGURE 18: NORTH AMERICA DRY EYE DISEASE MARKET, BY SECRETAGOGUES, 2023-2032 (IN $ MILLION)
FIGURE 19: NORTH AMERICA DRY EYE DISEASE MARKET, BY OTHER PRODUCTS, 2023-2032 (IN $ MILLION)
FIGURE 20: NORTH AMERICA DRY EYE DISEASE MARKET, GROWTH POTENTIAL, BY DISTRIBUTION CHANNEL, IN 2022
FIGURE 21: NORTH AMERICA DRY EYE DISEASE MARKET, BY HOSPITAL PHARMACIES, 2023-2032 (IN $ MILLION)
FIGURE 22: NORTH AMERICA DRY EYE DISEASE MARKET, BY INDEPENDENT PHARMACIES AND DRUGSTORES, 2023-2032 (IN $ MILLION)
FIGURE 23: NORTH AMERICA DRY EYE DISEASE MARKET, BY ONLINE PHARMACIES, 2023-2032 (IN $ MILLION)
FIGURE 24: NORTH AMERICA DRY EYE DISEASE MARKET, COUNTRY OUTLOOK, 2022 & 2032 (IN %)
FIGURE 25: UNITED STATES DRY EYE DISEASE MARKET, 2023-2032 (IN $ MILLION)
FIGURE 26: CANADA DRY EYE DISEASE MARKET, 2023-2032 (IN $ MILLION)